Physician profile
Robert S Castroll
NPI 1407929003
$19,836.65
in general payments reported to CMS, 2019-2025
37 companies · $3,151 in 2025
The $3,151 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,834 · 2020: $2,356 · 2021: $4,046 · 2022: $2,902 · 2023: $2,788 · 2024: $2,759 · 2025: $3,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,642 · Education: $55.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,642.33 |
| Education | $55.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,825.85 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,732.95 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Validus Pharmaceuticals LLC | $1,729.31 | 2019-2023 | Equetro |
| Alkermes, INC. | $1,644.05 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $1,482.56 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,436.85 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,369.24 | 2019-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $1,127.78 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,121.94 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $919.46 | 2023-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $742.99 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $700.05 | 2019-2025 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $459.78 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $348.64 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $338.76 | 2024-2025 | Cobenfy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $315.28 | 2019-2025 | Aplenzin, Wellbutrin |
| Alfasigma USA, INC. | $256.96 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $248.27 | 2022-2024 | Quviviq |
| Almatica Pharma LLC | $237.64 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Allergan, INC. | $234.74 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $234.52 | 2019-2022 | |
| Neuronetics, INC. | $230.31 | 2019-2024 | Neurostar Tms Therapy System |
| Eisai INC. | $198.91 | 2020-2022 | |
| Tris Pharma INC | $151.46 | 2022-2025 | Dyanavel Xr |
| Indivior INC. | $136.49 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $124.77 | 2021 | |
| Ironshore Pharmaceuticals INC. | $107.32 | 2019-2020 | |
| Shire North American Group INC | $76.97 | 2019 | |
| Orexo US, INC. | $74.11 | 2019-2025 | Zubsolv |
| Novo Nordisk INC | $65.03 | 2021 | |
| Corium, LLC | $37.18 | 2024 | Azstarys |
| Livanova USA, INC. | $27.75 | 2021 | |
| Avanir Pharmaceuticals, INC. | $24.89 | 2020 | |
| Supernus Pharmaceuticals, INC. | $23.41 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.44 | 2023 | |
| Currax Pharmaceuticals LLC | $16.63 | 2020 | |
| Kaleo, INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Castroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.